Led · Series B · Jun 2026

Founded in 2023 by self-driving veterans Oliver Cameron (CEO) and Jeff Hawke (CTO), Odyssey develops world models that gather and simulate physical-world data for applications across video, robotics and gaming. The company has produced a handful of models and is noted for generating rich, interactive video from text prompts. Its data-collection approach involved sending people with cameras to capture environments, mirroring techniques used by mapping products. After its latest financing Amazon became a strategic cloud partner and Odyssey plans to optimize its models for AWS Trainium chips. Financially, Odyssey raised $310 million in a Series B at a $1.45 billion valuation and has raised $337 million in total to date.

Participated · Equity · Dec 2025

Aether Biomachines combines purpose-built artificial intelligence with high-throughput robotics to create proteins that function as molecular assemblers for manufacturing and environmental applications. The company’s proprietary Protein Function Model, trained on in-house experimental data, has already generated seven new protein classes capable of extracting rare earth metals, recycling plastics, capturing CO₂, degrading PFAS, and enabling complex pharmaceutical synthesis. Its first commercial materials, RapidPrint and Ultra, are polymer additives that allow 3D-printed parts to be produced up to 10× faster and with 2× the strength of current industry benchmarks, a key advantage for defense and aerospace customers. Aether plans to scale these materials products while expanding its protein-design platform to address additional industrial challenges. The firm positions itself as a catalyst for a new industrial revolution by replacing large, costly chemical plants with nanoscale protein machinery that works more efficiently and sustainably. Total capital raised now stands at $64 million, providing resources to accelerate product commercialization and deepen partnerships across manufacturing, sustainability, and national security sectors.

Led · Series C · Jul 2025

Varda Space builds orbital manufacturing systems to produce biologics and other pharmaceutical components that benefit from microgravity-driven crystallization. The company is establishing a 10,000-square-foot laboratory in El Segundo, California to perform process engineering and identify which proteins and antibodies are best suited for space-based production. That lab is intended to generate intellectual property—Varda expects a higher volume of patent filings as it refines crystallization conditions and protocols. Varda has launched and returned three successful missions since 2023 and anticipates completing four missions this year. It has transitioned spacecraft manufacturing in-house after initially housing its manufacturing module inside Rocket Lab vehicles. The company also generates revenue by using its spacecraft as a hypersonic flight testbed for the U.S. Department of Defense, proposing a faster launch-and-return testing cadence and recoverable tested material. Varda operates orbital drug-manufacturing capsules that use microgravity to crystallize pharmaceutical compounds and returned its first capsule after a 10-month mission that successfully reformulated the HIV medicine ritonavir. The company has developed complementary terrestrial methods—including a hyper-gravity crystallization screening platform—and has begun publishing R&D results. Varda plans to scale from a single demonstration mission to a regular cadence of customer payload missions, with the next three already manifested with Rocket Lab and the next launch slated to land in Australia later this year. Leadership says the near-term focus is increasing flight cadence before prioritizing reusability, with capsule refurbishment and larger reactors targeted around 2027. Varda projects per-mission costs to fall from about $12 million for the initial flight to $5–6 million by mission four and roughly $2.5 million or less by mission ten. The company has a handful of signed contracts with publicly traded biotech customers and plans to focus solely on pharmaceuticals for the next decade or more. Varda Space is a startup focused on manufacturing in orbit, aiming to create a factory in space. The core offering is space-based manufacturing infrastructure and processes to produce goods in microgravity. According to the article, the company raised $42 million to support creation of its in-space production facility. The funding is described as enabling the development and construction of that factory. The article does not provide revenue, user metrics, investors, or additional financial details. Varda is building unmanned space-based manufacturing facilities to produce high-dollar-per-unit-mass products that can be brought back to Earth. The company focuses on manufacturing in space for terrestrial applications rather than 3D printing. Early target products mentioned include carbon nanotubes, fiber optic cables, organs and novel materials that could justify high launch costs. Varda was incubated at Founders Fund and is led by CEO and co-founder Will Bruey, a former SpaceX engineer. The firm envisions ramping its platform into broader space-manufacturing infrastructure and ultimately harvesting source materials in space via asteroid mining. Financially, Varda emerged with $9 million in outside funding to support its initial development and operations.

Led · Series B · Jan 2025

Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics intended to traverse tissue barriers and selectively target and reprogram activated cells only in regions of inflammation. Its targeted nanomedicine approach aims to improve precision medicine across ophthalmology, neurology, and inflammation by enabling selective modulation of diseased tissue. The company’s at-home monthly subcutaneously administered HDT for neovascular (wet) age-related macular degeneration and diabetic macular edema demonstrated a substantial reduction in treatment burden in interim data. Ashvattha is currently conducting an ongoing Phase 2 ophthalmology trial and a Phase 1/2 neuroinflammation trial and intends to use newly raised funds to complete those studies. Interim Phase 2 trial results will be presented by the principal investigator at the Angiogenesis 2025 meeting on February 8, 2025. The company was founded by Kannan Rangaramanujam, Sujatha Kannan, and Jeff Cleland and is based in Redwood City, California. Ashvattha develops hydroxyl dendrimer therapeutics (HDTs), a platform technology that chemically conjugates drugs to hydroxyl dendrimers to selectively target reactive inflammatory cells in diseased tissue. Its HDTs have demonstrated the ability to cross the blood-brain barrier and blood-retinal barrier, enabling programs in neurology, ophthalmology and systemic inflammatory conditions. Clinical-stage candidates include OP-101 (N‑acetyl cysteine conjugate) in a Phase 2 PRANA study for severe COVID-19, D-4517.2 for ocular neovascular disease, and OP-801 as an HD imaging agent for neuroinflammation; Ashvattha planned additional Phase 2 and Phase 1/2 starts in 2022 for wet AMD/DME and ALS. The company licenses the underlying HD platform from founders at Johns Hopkins and positions its pipeline around disease-cell selective delivery to increase therapeutic index. Proceeds from the announced financing and licensing are intended to advance multiple clinical-stage programs and preclinical candidates.

Participated · Equity · May 2024

Woodstock operates woodstock.club, a social investing app that enables users to buy U.S. stocks and ETFs from ¥1,000 and share portfolios and activity via a timeline. The product targets investment‑new Gen‑Z users: about 75% of account openers are aged 39 or younger and over 70% were investment beginners. The company recently completed a full UI redesign, simplifying navigation into Portfolio, Timeline and Search tabs, and added a “matching live‑trade” feature with swipe mechanics and AI‑powered stock trivia. Woodstock says the new discovery and live‑trade matching features are designed to make investing more intuitive for novices. The team plans to accelerate its securities business, add new financial products, and expand hiring to support growth. Financially, the firm has raised capital in this latest round to fund product development and business expansion. Woodstock operates woodstock.club, an SNS-style investing app that enables users to share information with other investors while investing in U.S. stocks and ETFs. The app offers access to over 500 U.S.-listed stocks and ETFs and allows market orders from ¥1,000; limit orders are not supported and the forex rate at execution applies. Orders placed while markets are closed are accepted as reservations and are executed when markets open. U.S. market access is provided via AlpacaJapan (the Japan arm of Alpaca). Woodstock launched an invite-only closed beta in October and, after receiving regulatory approval, formally launched on the 11th. The company was founded in March 2021 by Brian Jaehun Yun, Taisuke Kawamoto and Min Ju, is based in Tokyo, and plans to prepare for expansion into the U.S. and Asia. Woodstock also raised a seed round from Coinbase Ventures, Coral Capital, Hyper, Incubate Fund and Kindred Ventures; the amount was undisclosed.